Recent data showed that Acinetobacter baumannii and Pseudomonas aeruginosa — both of which landed the top spots on WHO’s list of “priority pathogens” in critical need of new therapies — were significantly more prevalent among patients hospitalized with carbapenem-resistant infections in the United States than the Enterobacteriaceae pathogens Escherichia coli and Klebsiella pneumoniae.
Date: Aug 23, 2017
Source: Healio
Via: Cai B, et al. Open Forum Infect Dis. 2017;doi:10.1093/ofid/ofx176.
Excerpt:
Recent data showed that Acinetobacter baumannii and Pseudomonas aeruginosa — both of which landed the top spots on WHO’s list of “priority pathogens” in critical need of new therapies — were significantly more prevalent among patients hospitalized with carbapenem-resistant infections in the United States than the Enterobacteriaceae pathogens Escherichia coli and Klebsiella pneumoniae.
According to Bin Cai, MD, MPH, MS, PhD, senior director at Shionogi Inc., a pharmaceutical company headquartered in Osaka, Japan, and colleagues, recent infection control measures addressing the substantial increase in carbapenem-resistant (CR) infections over the past decade have largely focused on preventing the spread of CR Enterobacteriaceae (CRE). However, the researchers noted that the frequency of other CR gram-negative pathogens, A. baumannii and P. aeruginosa, has also increased in recent years. Despite this, A. baumannii and P. aeruginosa were not “well appreciated” as a source of resistance transmission until WHO recognized them as equally concerning to public health earlier this year.
